التفاصيل البيبلوغرافية
| العنوان: |
Germline Testing Around the Globe: Challenges in Different Practice Settings. |
| المؤلفون: |
Al-Sukhun S; Al Hyatt Oncology Practice, Amman, Jordan., Masannat Y; Aberdeen Royal Infirmary, Scotland, United Kingdom.; The University of Aberdeen, Scotland, United Kingdom., Wegman-Ostrosky T; Subdirection of Research, Instituto Nacional de Cancerología, México City, Mexico., Shrikhande SV; Tata Memorial Centre, Mumbai, India., Manirakiza A; King Faisal Hospital, Kigali, Rwanda., Fadelu T; Division of Population Sciences, Dana Farber Cancer Institute, Boston, MA., Rebbeck TR; Division of Population Sciences, Dana Farber Cancer Institute, Boston, MA.; Harvard TH Chan School of Public Health, Boston, MA. |
| المصدر: |
American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting [Am Soc Clin Oncol Educ Book] 2023 May; Vol. 43, pp. e390522. |
| نوع المنشور: |
Journal Article |
| اللغة: |
English |
| بيانات الدورية: |
Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 101233985 Publication Model: Print Cited Medium: Internet ISSN: 1548-8756 (Electronic) Linking ISSN: 15488748 NLM ISO Abbreviation: Am Soc Clin Oncol Educ Book Subsets: MEDLINE |
| أسماء مطبوعة: |
Original Publication: Alexandria, Va. : American Society of Clinical Oncology |
| مواضيع طبية MeSH: |
Germ Cells* , Life Style*, Humans ; Public Health |
| مستخلص: |
Cancer is an increasing global public health burden. Lately, more emphasis has emerged on the importance of heredity in cancer, mostly driven by the introduction of germline genetic variants-directed therapeutics. It is true that 40% of cancer risk is attributed to modifiable environmental and lifestyle factors; still, 16% of cancers could be heritable, accounting for 2.9 of the 18.1 million cases diagnosed worldwide. At least two third of those will be diagnosed in countries with limited resources-low- and middle-income countries, especially where high rates of consanguine marriage and early age at diagnosis are already prevalent. Both are hallmarks of hereditary cancer. This creates a new opportunity for prevention, early detection, and recently therapeutic intervention. However, this opportunity is challenged by many obstacles along the path to addressing germline testing in patients with cancer in the clinic worldwide. Global collaboration and expertise exchange are important to bridge the knowledge gap and facilitate practical implementation. Adapting existing guidelines and prioritization according to local resources are essential to address the unique needs and overcome the unique barriers of each society. |
| تواريخ الأحداث: |
Date Created: 20230523 Date Completed: 20230525 Latest Revision: 20230525 |
| رمز التحديث: |
20240628 |
| DOI: |
10.1200/EDBK_390522 |
| PMID: |
37220318 |
| قاعدة البيانات: |
MEDLINE |
